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Introduction: Progranulin (PGRN), a pleiotropic growth factor, has emerged as an immunoregulatory molecule.
Because the roles of PGRN in dermatomyositis (DM) are still unknown, we investigated whether serum PGRN levels
are associated with disease activity and prognosis in DM patients, particularly in those with DM complicated with
interstitial lung disease (ILD).
Methods: The serum levels of PGRN were measured by enzyme-linked immunosorbent assay in patients with DM
(n =57; acute/subacute interstitial pneumonia (A/SIP): n =17, chronic interstitial pneumonia (CIP): n =24, without ILD:
n =16), polymyositis (PM, n =21; including 6 with ILD) and normal healthy controls (NHCs, n =60). We assessed the
correlation between the serum PGRN levels and the activity indexes of ILD or prognosis in DM patients with ILD.
Results: Serum PGRN levels were significantly higher in DM patients than in PM patients (P =0.0025) and in NHCs
(P <0.0001). In DM patients, the levels were significantly higher in patients with A/SIP than in those with CIP (P <0.0001)
or without ILD (P =0.0003). The serum PGRN levels in DM patients with ILD significantly correlated with serum ferritin
(rS =0.77, P <0.0001), lactate dehydrogenase (rS =0.54, P =0.0003) and C-reactive protein (rS =0.48, P =0.0015) levels.
Moreover, in DM patients with ILD, the cumulative survival rate for 6 months was significantly lower in the group with
serum PGRN levels ≥200 ng/ml (67%) than in the group with serum PGRN levels <200 ng/ml (100%) (P =0.0009).
Conclusions: Serum PGRN is associated with disease activity and prognosis of DM with ILD. PGRN may play a role in
the pathogenesis of DM and could be a useful biomarker.Introduction
Dermatomyositis (DM) is a systemic autoimmune and in-
flammatory disease that involves not only the muscle and
skin but also several other organs, such as the lungs, heart
and joints [1]. Interstitial lung disease (ILD) is the most
common internal organ manifestation, and it affects the
prognosis of DM patients. ILD is classified into two sub-
sets: acute/subacute interstitial pneumonia (A/SIP) and
chronic interstitial pneumonia (CIP) [2,3]. A/SIP is often
complicated with clinically amyopathic DM (CADM)
[4,5], which shows the typical skin manifestations of DM* Correspondence: tsukamot@intmed1.med.kyushu-u.ac.jp
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unless otherwise stated.but has no or little evidence of clinical myositis [6]. A/SIP
complicated with CADM is life-threatening and shows a
rapidly progressive pattern, with a 6-month survival rate
of 40.8%, irrespective of intensive therapy [5]. Combin-
ation therapy with prednisolone (PSL), cyclosporine A
(CsA) and intravenous pulse cyclophosphamide (IVCY) is
more effective for A/SIP with DM than PSL plus one
immunosuppressive agent [7]. Therefore, diagnosis and
evaluation of ILD is very important to determine the treat-
ment strategy when DM is diagnosed [8-10]. Although
several biomarkers that may reflect inflammatory activity
of lung have been utilized, such as ferritin [11-14] and
Krebs von den Lungen-6 (KL-6) [15-19], there are no
established serum biomarkers for DM-associated ILD.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cellular glycoprotein containing seven and one-half repeats
of cysteine-rich motifs. PGRN is proteolytically cleaved by
extracellular proteases, such as proteinase 3 (PR3) and
elastase, into granulin (GRN) [20] that range from 6 to
25 kDa. PGRN is abundantly expressed in rapidly cycling
epithelial cells, leukocytes, chondrocytes and neurons [21],
and its expression level is at steady state [22]. PGRN plays
a critical role in early embryogenesis [22], wound healing
[23], maintenance of neuronal survival [24] and tumori-
genesis [21]. Particularly, macrophage-derived PGRN is a
key regulatory factor in the processes of inflammation and
wound healing [23,25]. Recent mouse studies show that
mice unable to convert PGRN into GRN due to lack of
both elastase and PR3 cannot show inflammation in re-
sponse to injection of immune complexes [26]. These data
indicate that PGRN is synthesized by macrophages and is
cleaved into GRNs by elastase in tissues to enhance in-
flammation. Moreover, PGRN and/or GRN act as a soluble
cofactor for Toll-like receptor 9 (TLR9) signaling and en-
hance it [27]. We previously reported that serum PGRN
levels are significantly elevated in systemic lupus erythe-
matosus (SLE) patients in parallel with disease activities
and that PGRN may have a role in the pathogenesis of
SLE, partly by enhancing the TLR9 signaling and interleu-
kin (IL)-6 production [28]. Although macrophage activa-
tion is considered to underlie the pathogenesis of A/SIP
with DM [11-14] and TLR9 and IL-6 is associated with
DM [29-35], the roles of PGRN in DM are still unknown.
Here, we show that serum PGRN levels are signifi-
cantly elevated in DM patients, particularly those with
A/SIP, and are associated with disease activity and prog-
nosis of DM patients with ILD. PGRN may have a role
in the pathogenesis of DM.
Methods
Patients
We performed a cross-sectional study of patients who
were treated for DM or polymyositis (PM) at Kyushu
University Hospital, Saga University Hospital and Japanese
Red Cross Fukuoka Hospital between 2002 and 2013.
Fifty-seven Japanese patients with DM and twenty-one pa-
tients with PM were enrolled, and sera were obtained from
these patients. All of the patients fulfilled the criteria of
Bohan and Peter [36] for DM or PM or criteria for CADM
[37]. We defined active DM and PM patients who re-
quired the initiation or reinforcement of treatment (overall
disease activity). We excluded patients with other auto-
immune and infectious diseases. Each patient completed a
standardized medical history, including drug use, and was
given a physical examination. The information obtained
from the medical records of the patients included demo-
graphic data, such as age, sex, clinical manifestations of
DM and laboratory values. Serological profiling of eachpatient, including white blood cells (WBCs), lymphocytes,
hemoglobin (Hb), platelets (Plt), liver enzymes (aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
γ-glutamyl transpeptidase (γ-GTP)), creatine kinase (CK),
lactate dehydrogenase (LDH), ferritin, KL-6, C-reactive
protein (CRP), anti-nuclear antibody (ANA) and anti-Jo-1
antibody, was performed using the standard methods. The
serum samples from the patients with active DM were ac-
quired before the initiation or reinforcement of treatment,
and the samples from the patients with inactive DM were
acquired during regular hospital visits. The samples were
stored at −20°C. The active DM patients were treated with
corticosteroids or immunosuppressive drugs after the
completion of these evaluations. The sera obtained from
five DM patients with ILD were reevaluated after ILD was
ameliorated by treatment. Control sera were obtained
from healthy staff members (n =60) at Kyushu University
Hospital. This study was approved by the ethics com-
mittees of Kyushu University Hospital, Saga University
Hospital and Japanese Red Cross Fukuoka Hospital, and
the principles of the Declaration of Helsinki were followed
throughout the study. Informed consent was obtained
from all participants.
Measurement of PGRN
The serum PGRN levels were determined using enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
protocol. Briefly, calibrators, control sera and patients’ sera
(stored samples) were diluted and incubated with a mouse
monoclonal antibody against PGRN adsorbed onto the
microtiter plate wells. After washing, a mouse monoclonal
antibody against PGRN conjugated to horseradish perox-
idase was added, followed by a second washing step and
the addition of tetramethylbenzidine substrate. The inten-
sity of the blue color developed was in proportion to the
amount of PGRN bound in the initial step. The reaction
was terminated by the addition of 2 N sulfuric acid. The
absorbance was measured in a microtiter plate reader
(Thermo Fisher Scientific, Waltham, MA, USA) and
converted into nanograms per milliliter by plotting the
values against the PGRN titer of the calibrators/standards
given by the manufacturer. The assay range was 1.56 to
100 ng/ml.
Classification of ILD
ILD was assessed by radiography and high-resolution
computed tomography of the chest. ILD with DM was
divided into two forms: A/SIP and CIP. A/SIP is defined
as a rapidly progressive ILD within 3 months from the
onset of symptoms and radiographically diffuse alveolar
damage pattern or nonspecific interstitial pneumonias
(NSIP). CIP is defined as an asymptomatic, non–rapidly
progressive ILD or slowly progressive ILD over the
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or bronchiolitis obliterans with organizing pneumonia
pattern, according to the guidelines of the International
Consensus Statement of idiopathic Pulmonary Fibrosis
of the American Thoracic Society and the European
Respiratory Society [38]. The designation of A/SIP and
CIP was made blindly without knowledge of the labora-
tory results.Figure 1 Serum progranulin levels were elevated in patientsStatistical analysis
The differences between two groups were analyzed
using the Mann–Whitney U test. Fisher’s exact test was
used for comparison of frequencies. The Steel-Dwass
test was used for multiple comparisons among all
groups. The relationships between PGRN levels and
other continuous variables were analyzed using Spearman’s
rank correlation. Receiver operating characteristic (ROC)
analyses were performed for a mathematical expression
of different serum PGRN levels as cutoff points. The
cumulative survival rate was calculated using the
Kaplan-Meier test. The log-rank test was also used to
compare survival. P-values less than 0.05 were consid-
ered significant. All tests were two-tailed. All analyses
were performed using JMP statistical software (SAS In-
stitute, Cary, NC, USA).with dermatomyositis. Serum progranulin (PGRN) levels in 57
patients with dermatomyositis (DM), 21patients with polymyositis
(PM) and 60 normal healthy controls (NHCs), as measured by
enzyme-linked immunosorbent assay. The serum PGRN levels in DM
patients were significantly higher than those in NHCs.Results
Serum PGRN levels were markedly elevated in patients
with DM
Of the 57 patients with DM enrolled in the present
study, 49 were women, and 8 were men (active: n =40,
inactive: n =17). These patients ranged in age from 30
to 87 years (median age: 53 years). Of the 21 patients
with PM, 16 were women, and 5 were men (active:
n =11, inactive: n =10). These patients ranged in age
from 15 to 85 years (median age: 53 years). Among the
NHCs, 51 were women, and 9 were men. They ranged
in age from 20 to 59 years (median age: 32 years).
There were significant differences between patients
with DM or PM and NHCs in terms of age. However,
there was not a significant correlation between serum
PGRN levels and age in NHCs.
To investigate the association of PGRN with DM, we
first compared serum PGRN levels among 57 patients
with DM, 21 patients with PM and 60 NHCs by using
ELISA (Figure 1). Serum PGRN levels in NHCs were
always within the range of 35 to 70 ng/ml and distributed
normally. Serum PGRN levels in patients with PM
(median: 60 ng/ml) were significantly higher than in
healthy controls (48 ng/ml) (P <0.0001). Strikingly, serum
PGRN levels in patients with DM (median: 109 ng/ml)
were significantly and markedly higher than in PM
patients (P =0.0025) and in healthy controls (P <0.0001).Serum PGRN levels were elevated in DM patients with A/SIP
Because DM is occasionally complicated with ILD
[8-10], we next compared serum PGRN levels among
DM patients with A/SIP (n =17), those with CIP
(n =24) and those without ILD (n =16) (Figure 2).
Serum PGRN levels in DM patients with A/SIP (me-
dian: 228 ng/ml) were significantly higher than in DM
patients with CIP (75 ng/ml, P <0.0001) or without ILD
(79 ng/ml, P =0.0003). There was no significant differ-
ence between serum PGRN levels in DM patients with
CIP and those without ILD (P =0.8382). However,
serum PGRN levels in DM patients with CIP or
without ILD were significantly higher than in NHCs
(P <0.0001 and P =0.005, respectively; data not shown).
Comparison of clinical manifestations between DM
patients with A/SIP and without A/SIP
To evaluate clinical manifestations other than serum
PGRN levels, we compared those between DM patients
with A/SIP and without A/SIP (Table 1). There were no
significant differences among all the subsets in terms of
age and sex. The duration between the onset and eva-
luation in DM patients with A/SIP was significantly
Figure 2 Serum progranulin levels were elevated in
dermatomyositis patients with acute/subacute interstitial
pneumonia. Serum progranulin (PGRN) levels in 17 patients with
dermatomyositis (DM) with acute/subacute interstitial pneumonia
(A/SIP), 17 with chronic interstitial pneumonia (CIP) and 16 without
interstitial lung disease (ILD) are shown, as measured by enzyme-linked
immunosorbent assay. The serum PGRN levels in patients with DM with
A/SIP were significantly higher than in DM patients without A/SIP.
Table 1 Comparison of clinical manifestations between derma
pneumonia and without acute/subacute interstitial pneumon
Variables DM with A/SIP
Number of patients 17
Age, yr 54.0 (36 to 65)
Female, n (%) 14 (82.4)
Duration, mo 2 (1 to 19)
Muscle weakness, n (%) 4 (23.5)
WBCs, count/ml 5,200 (2,900 to 12,300)
Hb, g/dl 11.6 (7.9 to 13.9)
Plt, ×105/μl 22.2 (14.9 to 34.5)
CK, IU/L 209 (33 to 866)
AST, IU/L 74 (31 to 219)
ALT, IU/L 42 (19 to 111)
γ-GTP, IU/L 43 (16 to 346)
LDH, IU/L 392 (225 to 957)
Ferritin, ng/ml 875 (251 to 2,171)
KL-6, U/ml 959 (338 to 2,048)
PGRN, ng/ml 228 (70 to 586)
CRP, mg/dl 0.86 (0.03 to 2.97)
ANA >160, n (%) 1 (5.9)
Anti-Jo-1, n (%) 0 (0)
aANA, Anti-nuclear antibody; A/SIP, Acute/subacute interstitial pneumonia; ALT, Alanine
pneumonia; CK, Creatine kinase; CRP, C-reactive protein; DM, Dermatomyositis; γ-GTP,
Krebs von den Lungen-6; LDH, Lactate dehydrogenase; Plt, Platelets; WBC, White blood
and CRP indicate median (range). *P <0.05, **P <0.01, ***P <0.001 compared with DM
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muscle weakness was significantly lower in DM patients
with A/SIP than in those without it, indicating that the
ratio of CADM patients was significantly higher in DM
patients with A/SIP than in those without it. WBCs and
Hb tended to be lower in DM patients with A/SIP than
in those without it. Although CK levels showed no sig-
nificant difference among all the subsets, AST and ALT
levels were significantly higher in DM patients with A/
SIP than in those with CIP and without ILD. The levels
of LDH, ferritin, KL-6 and CRP, which are used as sero-
logic parameters for disease activity of ILD, showed sig-
nificant difference between DM patients with A/SIP and
those without A/SIP. The frequency of ANA or anti-Jo-1
positivity was not significantly different among all the
subsets.
Serum PGRN levels in DM patients with ILD correlated
with disease activities of ILD
We next tested whether serum PGRN levels in DM pa-
tients with ILD correlate with conventional serologic pa-
rameters for disease activity of ILD (Table 2). Serum
PGRN levels showed a significantly positive correlation
with serum levels of LDH (rS =0.54, P =0.0003), ferritin
(rS =0.77, P <0.0001) and CRP (rS =0.48, P =0.0015).tomyositis patients with acute/subacute interstitial
iaa
DM with CIP DM without ILD
24 16
54.5 (19 to 78) 36 (15 to 85)
20 (83.3) 15 (93.8)
33 (1 to 148)*** 11 (1 to 237)**
15 (62.5)* 15 (94.1)***
8,165 (2,900 to 14,990) 7,590 (3,540 to 11,580)
12.8 (10 to 15.4) 12.5 (9.8 to 15.3)
23.0 (12 to 38.8) 20.6 (6.2 to 37.7)
1,289 (16 to 12,300) 568 (51 to 2,646)
30 (14 to 657)** 44 (12 to 132)*
20 (11 to 301)* 31 (10 to 150)
24 (10 to 131) 26 (10 to 165)
273 (186 to 1,975)* 328 (157 to 489)*
88 (16 to 4,853)*** 105 (39 to 400)***
525 (188 to 1,802)* 224 (125 to 459)***
75 (43 to 221)*** 79 (31 to 207)***
0.24 (0.03 to 3.66)** 0.08 (0.01 to 0.9)***
2 (8.3) 5 (31.3)
4 (16.7) 0 (0)
aminotransferase; AST, Aspartate aminotransferase; CIP, Chronic interstitial
γ-glutamyl transpeptidase; Hb, Hemoglobin; ILD, Interstitial lung disease; KL-6,
cell. The values of age, duration, CK, AST, ALT, γ-GTP, LDH, ferritin, KL-6, PGRN
with A/SIP using the Mann–Whitney U test or Fisher’s exact test.
Table 2 Serum progranulin levels in dermatomyositis
patients with interstitial lung disease correlate with
disease activity of interstitial lung diseasea
Variables rS P-value
PGRN vs LDH 0.54 0.0003
PGRN vs ferritin 0.77 <0.0001
PGRN vs KL-6 0.26 0.1034
PGRN vs CRP 0.48 0.0015
aCRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, Lactate
dehydrogenase; PGRN, Progranulin; rS, Correlation coefficient established
employing Spearman’s correlation coefficients. Correlations between the serum
PGRN levels and LDH, ferritin, KL-6 and CRP are shown, as measured in 41 DM
patients with ILD.
Table 3 Treatment in each groupa




Number of patients 17 24 16
PSL or other agent alone, n (%) 3 (18) 8 (33) 12 (75)**
PSL 3 7 11
CNI 0 1 0
AZA 0 0 1
PSL + other agents, n (%) 14 (82) 16 (67) 3 (19)**
CNI 9 13 1
MTX 0 0 2
IVCY 0 1 0
CNI + MZB 0 1 0
CNI + IVCY 3 0 0
HSCT 2 1 0
aA/SIP, Acute/subacute interstitial pneumonia; AZA, Azathioprine; CIP, Chronic
interstitial pneumonia; CNI, Calcineurin inhibitor (cyclosporine or tacrolimus);
DM, Dermatomyositis; HSCT, Hematopoietic stem cell transplant; ILD,
Interstitial lung disease; IVCY, Intravenous pulse cyclophosphamide; MTX,
Methotrexate; MZB, Mizoribine; PSL, Prednisolone. **P <0.01 compared with
DM with A/SIP using Fisher’s exact test.
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serum levels of PGRN and KL-6 (rS =0.26, P =0.1034). In
five DM patients with active ILD that had subsided with
treatment, serum PGRN levels decreased in all of them
(Figure 3). These results indicate that serum PGRN levels
reflect disease activity of ILD in DM patients.
Treatment
The frequency of treatment with PSL alone was fairly low
in patients with DM with A/SIP, whereas the frequency of
treatment with immunosuppressive agents in addition to
PSL was significantly higher in DM patients with A/SIP
than in DM patients without ILD (P =0.0004) (Table 3).
Immunosuppressive agents used in patients with DM withFigure 3 Serum progranulin levels are decreased after
ameliorating the interstitial lung disease with treatment. Serum
progranulin (PGRN) levels before and after treatment in five patients
with active interstitial lung disease. The serum PGRN levels
decreased with the clinical amelioration of the disease.A/SIP were calcineurin inhibitors (CNIs: CsA or tacro-
limus) for nine patients and the combination therapy
with CNI plus IVCY for three patients. We performed
hematopoietic stem cell transplants (HSCTs) for two
refractory DM patients with A/SIP, irrespective of the
combination therapy with PSL, CNI plus IVCY, and
could rescue them [39].
Serum PGRN levels in DM patients with ILD were
associated with prognosis
Because DM with ILD is occasionally life-threatening
[4,5,7], in order to define the optimal cutoff point with
the highest diagnostic accuracy in terms of survival, we
performed ROC curve analysis for distinct serum PGRN
levels. The highest area under the curve was calculated
for a baseline serum PGRN level of 200 ng/ml. The two
subsets were classified by serum PGRN level of 200 ng/ml.
The cumulative survival rates for 6 months were 66.7% and
100% in the group with serum PGRN levels ≥200 ng/ml
(n =12), including two patients treated with HSCT, and
the group with serum PGRN levels <200 ng/ml (n =29)
in DM with ILD, respectively (Figure 4). The cumula-
tive survival rate was significantly lower in the group
with serum PGRN levels ≥200 ng/ml than in the group
with serum PGRN levels <200 ng/ml (P =0.0009). These
results suggest that baseline serum PGRN levels predict
the prognosis of DM patients with ILD.
Discussion
To our knowledge, this is the first study to show that
PGRN levels were significantly elevated in sera of DM
patients, in particular those with A/SIP, and these
Figure 4 Serum progranulin levels in dermatomyositis patients
with interstitial lung disease were associated with prognosis.
The cumulative survival rate for 6 months in the serum progranulin
(PGRN) <200 ng/ml group and the ≥200 ng/ml group of patients
with dermatomyositis with interstitial lung disease are shown. The
cumulative survival rate was calculated using the Kaplan-Meier test.
The log-rank test was also used to compare survival. The cumulative
survival rate was significantly lower in the group with serum
PGRN levels ≥200 ng/ml than in the group with serum PGRN
levels <200 ng/ml.
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and prognosis of DM patients with ILD.
Consistent with previous reports [11,12], the elevation
of transaminases and hyperferritinemia were observed in
DM with A/SIP in the present study. In addition, WBC
and Hb tended to be lower in DM patients with A/SIP
than in those without it. These facts suggest that macro-
phages are substantially activated and cause injury to the
lungs and the liver in DM patients with A/SIP. Actually,
the accumulation of ferritin-producing macrophages has
been shown in a CADM-related acute interstitial pneumo-
nia autopsy case [40]. Because PGRN is highly expressed
in macrophages [22], elevation of serum PGRN levels in
DM with A/SIP also reflects macrophage activation as that
of ferritin.
In the present study, other than DM, we also measured
concentrations of serum PGRN in patients with PM
(n =21), including 6 with ILD (median: 59 ng/ml) and 15
with systemic sclerosis (median: 49 ng/ml) (same levels in
NHCs), including 13 with ILD (median: 49 ng/ml). In our
data, although sera from PM patients contained signifi-
cantly elevated PGRN compared with NHCs, DM patients’
sera had much higher levels of PGRN, especially among
DM patients who also had A/SIP. This difference may
occur because activated macrophages appeared especially
in DM patients with A/SIP. Although we could not recruit
acute respiratory distress syndrome (ARDS) patients into
this study, ARDS could be an additional control to deter-
mine whether PGRN is a more general marker of acute re-
spiratory inflammation.
PGRN is reported to be important in the initiation of
inflammation by recruiting fibroblasts, macrophages andneutrophils to the site of inflammation [23]. PGRN is
also converted to GRN by the elastase that is produced
by leukocytes and other cells [41], however, and recent
mouse studies have shown that GRN possesses inflam-
matory functions [25,26,42]. Thus, PGRN may be con-
verted to GRN in the lungs and may be associated with
the early phase of pathogenesis in DM with A/SIP. How-
ever, it is difficult to investigate the function of GRN in
human studies, because we cannot measure GRNs at
this moment.
Serum PGRN levels showed a significantly positive cor-
relation with serum levels of LDH (rS =0.54, P =0.0003)
(Table 2) and ferritin (rS =0.77, P <0.0001). However, there
was no significant correlation between serum levels of
PGRN and those of KL-6, another biomarker for ILD. Re-
cent studies suggest serum ferritin levels as a marker for
severity of acute progressive ILD in DM and CADM pa-
tients [11-14]. The serum ferritin concentrations in
CADM patients with A/SIP are already elevated in early
stages of the disease, before progression of ILD [11]. LDH
and surfactant protein D are released into the blood when
pulmonary cells are damaged with inflammation [43]. KL-
6 rather reflects the regeneration and proliferation of
pneumocytes after the damage of the pulmonary tissue
[44]. Thus, PGRN could also be an acute marker for ILD
as well as ferritin and LDH.
When we compared clinical manifestations between
DM patients with A/SIP and without A/SIP, the fre-
quency of CADM was significantly higher in those with
A/SIP (76.5%) than in those with CIP (37.5%) and in
those without ILD (5.9%). CADM may be a useful indi-
cator for the occurrence of A/SIP. The levels of CRP
showed significant differences between DM patients with
A/SIP and those without and correlated with serum
PGRN levels (rS =0.48, P =0.0015) (Table 2). We previ-
ously reported that serum PGRN levels are elevated in
SLE patients and that PGRN stimulated IL-6 production
via TLR9 [28]. Upregulated IL-6 production stimulated
by PGRN [27,28,45] may be related to elevation of CRP
in DM patients with A/SIP. Serum IL-6 levels were sig-
nificantly higher in dead than alive CADM patients with
ILD [33] and were reported to be candidate biomarkers
for disease activity in DM [32] and SLE [46]. Because
TLR9 is highly expressed in DM [29-31] and SLE [47],
upregulated IL-6 production stimulated by PGRN via
TLR9 may be a common pathogenesis of DM and SLE.
However, the proposed role of PGRN signaling via TLR9
in DM must be directly demonstrated in future studies.
Elevated serum PGRN levels have been noted for a num-
ber of other pathological conditions [48]. So, PGRN is
most likely not a disease-specific marker, but rather is
probably a marker of immune activation.
Most of the DM patients with CIP were treated with
PSL and immunosuppressive agents. HSCT was performed
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In contrast, several patients with A/SIP required combin-
ation therapy with PSL, CNI and IVCY (and HSCTs). This
distinction might be responsible for cellular phenotypes
affecting the pathogenesis of ILD.
The cumulative survival rate was significantly lower in
the group with serum PGRN levels ≥200 ng/ml than in the
group with serum PGRN levels <200 ng/ml (P =0.0009)
(Figure 4). These data indicate that baseline serum PGRN
levels can predict survival. The group with serum PGRN
levels ≥200 ng/ml included two refractory patients with
A/SIP treated with HSCTs, which saved their lives. If we
had not been able to rescue them, the survival rate in the
group with serum PGRN levels ≥200 ng/ml would have
been lower. It is inferred from our findings that the inten-
sive combination therapy with various immunosuppressive
agents should be chosen for DM patients with ILD show-
ing high serum PGRN levels, especially ≥200 ng/ml.
We must acknowledge some limitations of this study.
The sample size of our study was small. Statistical tests
usually require a larger sample size to justify that the effect
did not happen by chance alone. Moreover, owing to the
study’s cross-sectional design, it is difficult to establish the
exact and definite causal relationships, except the associ-
ation between PGRN and development of ILD with DM,
on the basis of the collected data. There were potential
confounding effects of medication use on serum PGRN
levels in patients with inactive DM with CIP and without
ILD. Last, to fully validate PGRN as a predictive bio-
marker, we need to show that elevated PGRN levels pre-
date clinical respiratory decompensation.
Conclusions
In conclusion, this pilot study demonstrates that the
serum PGRN levels were elevated in patients with DM, in
particular those with A/SIP, and were correlated with dis-
ease activity and prognosis of DM patients with ILD.
PGRN could be a useful biomarker for disease activity and
a predictor of survival in DM patients with ILD. These
findings of the study will provide new insights into the
pathogenesis as well as the therapy of DM, and will shed
new light on the dysregulation of the immune system in
autoimmune diseases. Further studies are required to re-
veal more precisely the mechanisms of PGRN in human
autoimmune diseases.
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